Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2

Technology appraisal guidance
Reference number: TA257
Published: 27 June 2012

Download guidance (PDF)

6 Related NICE guidance

Advanced breast cancer: diagnosis and treatment. NICE clinical guideline 81 (2009).
Familial breast cancer: the classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care. NICE clinical guideline 41 (2006).
Guidance on the use of trastuzumab for the treatment of advanced breast cancer. NICE technology appraisal guidance 34 (2002).
Guidance on the use of eribulin for the treatment of locally advanced or metastatic breast cancer. NICE technology appraisal guidance 250 (2012).